Organ Damage and Quality of Life in Antiphospholipid Syndrome

Current Rheumatology Reports

Volumn 18, Issue 2, 2016, Pages 1-7

  Alba, P ^a   Gomez Puerta J A ^b   Goycochea Robles, M V ^c   Amigo, M C ^c  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Antiphospholipid syndrome (APS); Damage index in APS (DIAPS); Health related quality of life (HRQoL); Organ damage; Quality of life; SLICC ACR Damage Index (SDI); Systemic autoimmune diseases (SAD)

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; DAMAGE INDEX IN ANTIPHOSPHOLIPID SYNDROME; DIAGNOSTIC ACCURACY; DISEASE ASSESSMENT; HUMAN; MORBIDITY; MORTALITY; ORGAN INJURY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SLICC/ACR DAMAGE INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS; COMPLICATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PSYCHOMETRY; SEVERITY OF ILLNESS INDEX; THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS; PSYCHOMETRICS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; THROMBOSIS;

EID: 84954420405     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-015-0556-6     Document Type: Review

References (59)

1. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus. 2000;9:322–7.
2. Fischer-Betz R, Schneider M. Connective tissue diseases: evaluation of clinical response. Rheumatology (Oxford). 2008;47(2):234–5.
3. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
4. Merashli M, Hassan M, Noureldine A, et al. Antiphospholipid syndrome: an update. Eur J Clin Invest. 2015;45:653–62.
5. Amigo MC. What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)? Lupus. 2014;23:1259–61.
6. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303–8.
7. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19:508–12.
8. Jallow T, D’Cruz D, Lempp H. Antiphospholipid syndrome. BMJ. 2015;350:h1426.
9. Sharma P, Scotland G, Cruickshank M, Tassie E, Fraser C, Burton C, Croal B, Ramsay CR, Brazzelli M. Is self.monitoring an effective option for people receiving long-term vitamin K antagonist therapy? A systematic review and economic evaluation. BMJ Open 2015 (6): e007758.
10. Gladman DD, Urowitz MB, Goldsmith CH, Bacon P, Fortin P, Ginzler E, et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809–13.
11. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/ American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol. 2000;27:373–6.
12. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10:93–6.
13. Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol. 2002;29:1398–400.
14. Cardoso CR, Signorelli FV, Papi JA, Salles GF. Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study. Lupus. 2008;17:1042–8.
15. Goncalves MJ, Sousa S, Inès LS, et al. Characterization of damage in Portuguese lupus patients: analysis of a National Lupus Registry. Lupus. 2015;24:256–62.
16. Ruiz Irastorza G, Egurbide MV, Martinez-Berriotxoa A, et al. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus. 2004;13:900–5.
17. Ruiz Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004;164:77–82.
18. Cervera R, Serrano R, Pons-Estel GJ, on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies), et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74:1011–8. An important paper describing a series of 1000 European APS patients with a long term follow-up.
19. Grika EP, Ziakas PD, Zintzaras E, et al. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol. 2012;39:516–23. This study describes morbidity, organ damage, and cause of death in Greek patients with APS after a long-term follow-up.
20. Barbhaiya M, Erkan D, Rodriguez-Alamraz E, Ramón G, Vega J, Lockshin MD. Utility of the Systemic Lupus International Collaborating Clinics (SLICC) American College of Rheumatology (ACR) Damage Indexfor antiphospholipid antibody (aPL) positive patients. Arthritis Rheum. 2011;63:Suppl:S3.
21. Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015;24:927–34. This paper is of importance as it describes for the first time, the development of a specific damage index for thrombotic APS.
22. Holzer LA, Sevelda F, Fraberger G, Bluder O, Kickinger W, Holzer G. Body image and self-esteem in lower-limb amputees. PLoS One. 2014;9:e92943.
23. Erkan D, Yazici Y, Sobel R, Lockshin MD. Primary sntiphospholipid syndrome: functional outcome after 10 years. J Rheumatol. 2000;27:2817–21.
24. Dall’Ara F, Reggia R, Taraborelli M, Andreoli L, Taglietti M, Frassi M, et al. Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality. Lupus. 2014;23:1255–8.
25. Tektonidou MG, Ioannidis JP, Boki KA, et al. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM. 2000;93:523–30.
26. Ugolini Lopes M, Aguila L, Tonon R et al. SLICC and DIAPS. Potential indices for damage assessment in primary antiphospholipid syndrome (PAPS). Presented at APLA & LACA 2013, 14th International Congress on Antiphospholipid Antibodies. 18–21 September 2013. Rio de Janeiro, Brazil.
27. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.
28. Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2003;5:395–400.
29. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore). 1998;77:195–207.
30. Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, de la Red G, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730–6.
31. Gómez-Puerta JA, Cervera R, Espinosa G, Asherson RA, García-Carrasco M, da Costa IP, et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis. 2007;66:740–6.
32. Cervera R, Bucciarelli S, Plasin MA, Gómez-Puerta JA, Plaza J, Pons-Estel GJ, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun. 2009;32:240–5.
33. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–4.
34. Cervera R, Font J, Gómez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205–9.
35. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54:2568–76.
36. Asherson RA, Cervera R, Klumb E, Stojanovic L, Sarzi-Puttini P, Yinh J, et al. Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum. 2008;38:124–31.
37. Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003;62:530–3.
38. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Semin Arthritis Rheum. 2013;42:417–23.
39. WHOQOL User manual. Geneva.World Health Organization 1998:61–71.
40. Boers M, Brooks P, Strand V, et al. The OMERACT filter for outcomes measures in rheumatology. J Rheumatol. 1998;25:198–9.
41. Geryk LL, Carpenter DM, Blalock SJ, De Vellis RF, Jorda JM. The impact of co-morbidity on HRQL in rheumatoid arthritis and osteoarthritis patients. Clin Exp Rheumatol. 2015;33:366–74.
42. Strand V, Singh JA. Improved Health related Quality of Life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2007 Suppl 9:S237-251.
43. Ware JE, Sherburne CD. The MOS 36-item short form health survey (SF36) I: concept framework and item election. Med Care. 1992;30:473–83.
44. Euro-Qol A new facility for the measurement of health-related quality of life. Te EuroQol group. Health policy 1990;16:199–208.
45. Picavet HSJ, Hoeymans. Health related quality of life in multiple musculoskeletal diseases: SF36 and EQ-ED in the DMC3 study. Annals Rheum Dis. 2004;63:723–729.
46. Use of sort form SF36 for health status in British patients with RA. Reliability, validity and responsiveness of the sort form 36-item health survey. Br J Rheumatol 1998;37:425–436.
47. Ware JE. SF-36 health survey update. Lincoln: Quality-Metric Incorporated; 2007.
48. Wang S-l, Wu B, Zhu L-a, Leng L, Bucala R, et al. Construct and criterion validity of the euro Qol-5D in patients with systemic lupus erythematosus. PLoS One. 2014;9:e98883. doi:10.1371/journal.pone.0098883.
49. Wang C, Mayo N, Fortin P. The relationship between related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol. 2001;28:3.
50. García-Carrasco M, Mendoza-Pinto C, Cardiel MH, Méndez-Martínez S, García-Villaseñor A, Jiménez-Hernández C, et al. Health related quality of life in mexican women with systemic lupus erythematosus: a descriptive study using SF36 and LupusQol. Lupus. 2012;21:1219–24. This descriptive study evaluated HRQoL in a large group of Mexican SLE patients.
51. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus an update. Ann Acad Med Singap. 2007;36:115–22.
52. Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis. Thromb J. 2015;13:16. Important review demonstrating differences between thrombosis associated with SLE and, with APS.
53. Balitsy AK, Peeva V, Su J, et al. Thrombovascular events affect quality of life in patients with systemic lupus erythematosus. J Rheumatol. 2011;38:1017–9.
54. Mevorach-Zussman N, Bolotin A, Shalev BA, Bilenko N, Mazor M, Bashiri A. Anxiety and deterioration of quality of life factors associated with recurrent miscarriage in an observational study. J Perinat Med. 2012;40:495–501. An important paper describing QoL in cases with recurrent miscarriage, includingAPS patients.
55. Mathew S, Cesario S, Symes L. Explaining “unexplainded” perinatal loss. Experiences of women with antiphospholipid syndrome. J Perinat Neonat Nurs. 2008;22:293–301.
56. Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, Khamashta. Efficacy and safety of long-term low molecular weight heparin in patiens with antiphospholipid syndrome. Ann Rheum Dis. 2011;70:1652–1654.
57. Hasan SS, Teh KM, Ahmed SI, Chong DW, Ong HC, Naina B. Quality of life (QoL) and international normalized ratio (INR) control of patients attending anticoagulation clinics. Public Health. 2015;129:954–62.
58. Georgopoulou S, Efraimidou S, MacLennan SJ, Ibrahim F, Cox T. Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using SF36. Lupus. 2015;24:174–9. First survey that evaluates population with APS exploring patients qualitative view of their disease.
59. Zuily S. Rat AC, Regnault V, Kaminsky P, Mismetti P, Ninet J, Baillet N, Magy-Bertrand N. Pasquali J-L, Lambert M, Pasquier E, Lorcerie B, Lecompte L, Guillemin F, Whal D. and TAC(1)C investigators. Impairment of quality of life in patients with antiphospholipid syndrome. Lupus. 2015;24:1161–1168. Highly recommended survey that compares the quality of life in patients with APS, SLE, and the general population. Cardiovascular comorbidities and thrombosis are considered.